FBLG

+ Watchlist + Portfolio

FibroBiologics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.19
52-Week Range: $0.62 – $12.80
Market Cap: $8.59M
P/E (TTM): —
EPS (TTM): -5.51
Dividend Yield: —

Advanced Metrics

Price/Book: 1.69
PEG Ratio: —
Return on Equity: -660.08%
Return on Assets: -95.77%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.64
Debt/Equity: 0.32
Total Debt: $1.46M
Free Cash Flow: $-8.37M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $6.54M

FBLG Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.15M	$2.37M	$4.50M	$7.41M
Selling, General & Admin	$3.32M	$6.52M	$9.23M	$9.24M
Operating Expenses	$4.47M	$8.89M	$13.74M	$16.65M
Operating Income	-$4.47M	-$8.89M	-$13.74M	-$16.65M
EBITDA	-$4.37M	-$15.90M	-$10.57M	-$17.61M
Pretax Income	-$5.12M	-$16.48M	-$11.16M	-$18.65M
Net Income	-$5.12M	-$16.48M	-$11.16M	-$18.65M
Diluted EPS	-3.15	-11.74	-6.80	-8.40
Diluted Shares	1.62M	1.62M	1.64M	2.23M

FBLG Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$2.27M	$9.16M	$13.98M	$4.89M
Receivables	$300.00K	$0.00	—	—
Current Assets	$2.63M	$9.21M	$14.23M	$6.35M
Total Assets	$4.82M	$11.82M	$16.45M	$9.62M
Current Liabilities	$7.07M	$9.18M	$12.73M	$1.76M
Total Debt	$7.52M	$1.75M	$10.55M	$2.41M
Total Liabilities	$8.82M	$10.57M	$13.71M	$3.46M
Retained Earnings	-$7.87M	-$24.36M	-$35.52M	-$54.16M
Shareholders' Equity	-$4.00M	$1.25M	$2.73M	$6.16M
Working Capital	-$4.45M	$32.00K	$1.50M	$4.59M
Net Debt	$3.19M	—	—	—

FBLG Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$4.07M	-$6.40M	-$11.90M	-$16.39M
Capital Expenditure	—	-$495.00K	-$184.00K	-$262.00K
Free Cash Flow	-$4.07M	-$6.90M	-$12.09M	-$16.66M
Depreciation & Amortisation	$94.00K	$437.00K	$573.00K	$832.00K
Stock-Based Compensation	$265.00K	$1.76M	$2.22M	$2.69M
Investing Cash Flow	$0.00	-$495.00K	-$184.00K	-$262.00K
Financing Cash Flow	$5.92M	$13.79M	$16.91M	$7.57M
Net Change in Cash	$1.86M	$6.90M	$4.82M	-$9.09M

FBLG Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.78M	$2.04M	$2.79M	$797.00K	$2.95M
Selling, General & Admin	$2.75M	$2.45M	$2.25M	$1.79M	$2.12M
Operating Expenses	$4.53M	$4.49M	$5.04M	$2.59M	$5.07M
Operating Income	-$4.53M	-$4.49M	-$5.04M	-$2.59M	-$5.07M
EBITDA	-$4.80M	-$4.45M	-$5.55M	-$2.81M	-$4.76M
Pretax Income	-$4.97M	-$4.66M	-$5.78M	-$3.24M	-$5.00M
Net Income	-$4.97M	-$4.66M	-$5.78M	-$3.24M	-$5.00M
Diluted EPS	-2.71	-2.40	-2.60	—	-1.33
Diluted Shares	1.83M	1.93M	2.15M	—	3.77M

FBLG Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$8.67M	$8.85M	$4.87M	$4.89M	$1.48M
Current Assets	$9.33M	$10.18M	$5.24M	$6.35M	$2.90M
Total Assets	$11.43M	$13.91M	$8.74M	$9.62M	$5.94M
Current Liabilities	$8.21M	$10.96M	$6.72M	$1.76M	$1.83M
Total Debt	$7.12M	$10.78M	$7.11M	$2.41M	$2.48M
Total Liabilities	$9.08M	$13.05M	$8.62M	$3.46M	$3.34M
Retained Earnings	-$40.48M	-$45.14M	-$50.92M	-$54.16M	-$59.16M
Shareholders' Equity	$2.35M	$860.00K	$125.00K	$6.16M	$2.60M
Working Capital	$1.12M	-$786.00K	-$1.48M	$4.59M	$1.08M

FBLG Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.28M	-$3.98M	-$3.97M	-$3.16M	-$4.36M
Capital Expenditure	-$43.00K	-$213.00K	-$6.00K	—	—
Free Cash Flow	-$5.32M	-$4.20M	-$3.98M	-$3.16M	-$4.36M
Depreciation & Amortisation	$161.00K	$206.00K	$231.00K	$234.00K	$237.00K
Stock-Based Compensation	$551.00K	$729.00K	$704.00K	$702.00K	$694.00K
Investing Cash Flow	-$43.00K	-$213.00K	-$6.00K	$0.00	$0.00
Financing Cash Flow	$0.00	$4.38M	$0.00	$3.19M	$952.00K
Net Change in Cash	-$5.32M	$178.00K	-$3.98M	$27.00K	-$3.41M

Market Snapshot

About

FibroBiologics, Inc. is a clinical-stage biotechnology company focused on developing cell-based therapies using fibroblast cells. The company's proprietary platform technology leverages the regenerative properties of fibroblasts to treat degenerative diseases, cancer, and wound healing applications. FibroBiologics is developing a pipeline of therapeutic candidates targeting conditions including multiple sclerosis, degenerative disc disease, and various oncology indications. The company's approach seeks to harness the immunomodulatory and tissue-regenerative capabilities of fibroblast cells to address unmet medical needs across multiple therapeutic areas.